Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 6/2017

01-06-2017 | Case Report

Oral cyclophosphamide was effective for Coombs-negative autoimmune hemolytic anemia in CD16+CD56− chronic lymphoproliferative disorder of NK-cells

Authors: Nodoka Sekiguchi, Sayaka Nishina, Toru Kawakami, Hitoshi Sakai, Noriko Senoo, Yasushi Senoo, Toshiro Ito, Hiroshi Saito, Hideyuki Nakazawa, Tomonobu Koizumi, Fumihiro Ishida

Published in: International Journal of Hematology | Issue 6/2017

Login to get access

Abstract

An 84-year-old woman was referred to our hospital presenting anemia. Her hemoglobin level was 5.8 g/dL, and white blood cell count was 9400/μL, consisting of 82% lymphocytes. Given the lymphocyte phenotype (CD2+, CD3−, CD16+, and CD56−) and negative whole blood EBV viral load, we made a diagnosis of chronic lymphoproliferative disorder of NK cells (CLPD-NK). We suspected hemolytic anemia because of the high levels of reticulocytes in the peripheral blood and the low haptoglobin value. Although the direct Coombs test was negative and there was no cold agglutination, we examined her red-blood-cell-bound IgG (RBC-IgG), which was elevated. She was diagnosed as having as Coombs-negative autoimmune hemolytic anemia (AIHA). We report the effectiveness of oral cyclophosphamide for Coombs-negative autoimmune hemolytic anemia in CLPD-NK.
Literature
1.
Tefferi A, Li CY, Witzig TE, Dhodapkar MV, Okuno SH, Phyliky RL. Chronic natural killer cell lymphocytosis: a descriptive clinical study. Blood. 1994;84(8):2721–5.PubMed
2.
Bible KC, Tefferi A. Cyclosporine A alleviates severe anaemia associated with refractory large granular lymphocytic leukaemia and chronic natural killer cell lymphocytosis. Br J Haematol. 1996;93(2):406–8.CrossRefPubMed
3.
Ishida F, Matsuda K, Sekiguchi N, Makishima H, Taira C, Momose K, et al. STAT3 gene mutations and their association with pure red cell aplasia in large granular lymphocyte leukemia. Cancer Sci. 2014;105(3):342–6.CrossRefPubMedPubMedCentral
4.
Kawahara S, Sasaki M, Isobe Y, Ando J, Noguchi M, Koike M, et al. Clinical analysis of 52 patients with granular lymphocyte proliferative disorder (GLPD) showed frequent anemia in indolent T-cell GLPD in Japan. Eur J Haematol. 2009;82(4):308–14.CrossRefPubMed
5.
Dearden C. Large granular lymphocytic leukaemia pathogenesis and management. Br J Haematol. 2011;152(3):273–83.CrossRefPubMed
6.
Kamesaki T, Oyamada T, Omine M, Ozawa K, Kajii E. Cut-off value of red-blood-cell-bound IgG for the diagnosis of Coombs-negative autoimmune hemolytic anemia. Am J Hematol. 2009;84(2):98–101.CrossRefPubMed
7.
Andersson EI, Tanahashi T, Sekiguchi N, Gasparini VR, Bortoluzzi S, Kawakami T, et al. High incidence of activating STAT5B mutations in CD4-positive T-cell large granular lymphocyte leukemia. Blood. 2016;128(20):2465–8.CrossRefPubMedPubMedCentral
8.
Alekshun TJ, Sokol L. Diseases of large granular lymphocytes. Cancer Control. 2007;14(2):141–50.PubMed
9.
Huang Q, Chang KL, Gaal KK, Weiss LM. An aggressive extranodal NK-cell lymphoma arising from indolent NK-cell lymphoproliferative disorder. Am J Surg Pathol. 2005;29(11):1540–3.CrossRefPubMed
10.
Oshimi K. Progress in understanding and managing natural killer-cell malignancies. Br J Haematol. 2007;139(4):532–44.CrossRefPubMed
11.
12.
Rabbani GR, Phyliky RL, Tefferi A. A long-term study of patients with chronic natural killer cell lymphocytosis. Br J Haematol. 1999;106(4):960–6.CrossRefPubMed
13.
Morice WG, Leibson PJ, Tefferi A. Natural killer cells and the syndrome of chronic natural killer cell lymphocytosis. Leuk Lymphoma. 2001;41(3–4):277–84.CrossRefPubMed
14.
Kaito K, Otsubo H, Ogasawara Y, Shimada T, Kasama K, Yahagi Y, et al. Severe aplastic anemia associated with chronic natural killer cell lymphocytosis. Int J Hematol. 2000;72(4):463–5.PubMed
15.
Bockorny B, Dasanu CA. Autoimmune manifestations in large granular lymphocyte leukemia. Clin Lymphoma Myeloma Leuk. 2012;12(6):400–5.CrossRefPubMed
16.
Poullot E, Zambello R, Leblanc F, Bareau B, De March E, Roussel M, et al. Chronic natural killer lymphoproliferative disorders: characteristics of an international cohort of 70 patients. Ann Oncol. 2014;25(10):2030–5.CrossRefPubMedPubMedCentral
17.
Evans RS, Weiser RS. The serology of autoimmune hemolytic disease; observations on forty-one patients. AMA Arch Intern Med. 1957;100(3):371–99.CrossRefPubMed
18.
Kajii E, Omi T, Miura Y, Ikemoto S. A new approach for diagnosis of autoimmune hemolytic anemia. Rinsho Ketsueki. 1994;35(4):336–40.PubMed
19.
Fisch P, Handgretinger R, Schaefer HE. Pure red cell aplasia. Br J Haematol. 2000;111(4):1010–22.CrossRefPubMed
20.
Handgretinger R, Geiselhart A, Moris A, Grau R, Teuffel O, Bethge W, et al. Pure red-cell aplasia associated with clonal expansion of granular lymphocytes expressing killer-cell inhibitory receptors. N Engl J Med. 1999;340(4):278–84.CrossRefPubMed
21.
Zambello R, Semenzato G. Large granular lymphocyte disorders: new etiopathogenetic clues as a rationale for innovative therapeutic approaches. Haematologica. 2009;94(10):1341–5.CrossRefPubMedPubMedCentral
22.
Moignet A, Hasanali Z, Zambello R, Pavan L, Bareau B, Tournilhac O, et al. Cyclophosphamide as a first-line therapy in LGL leukemia. Leukemia. 2014;28(5):1134–6.CrossRefPubMed
23.
Go RS, Li CY, Tefferi A, Phyliky RL. Acquired pure red cell aplasia associated with lymphoproliferative disease of granular T lymphocytes. Blood. 2001;98(2):483–5.CrossRefPubMed
24.
Fujishima N, Sawada K, Hirokawa M, Oshimi K, Sugimoto K, Matsuda A, et al. Long-term responses and outcomes following immunosuppressive therapy in large granular lymphocyte leukemia-associated pure red cell aplasia: a Nationwide Cohort Study in Japan for the PRCA Collaborative Study Group. Haematologica. 2008;93(10):1555–9.CrossRefPubMed
25.
26.
Bareau B, Rey J, Hamidou M, Donadieu J, Morcet J, Reman O, et al. Analysis of a French cohort of patients with large granular lymphocyte leukemia: a report on 229 cases. Haematologica. 2010;95(9):1534–41.CrossRefPubMedPubMedCentral
27.
Loughran TP Jr, Zickl L, Olson TL, Wang V, Zhang D, Rajala HL, et al. Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998). Leukemia. 2015;29(4):886–94.PubMed
Metadata
Title
Oral cyclophosphamide was effective for Coombs-negative autoimmune hemolytic anemia in CD16+CD56− chronic lymphoproliferative disorder of NK-cells
Authors
Nodoka Sekiguchi
Sayaka Nishina
Toru Kawakami
Hitoshi Sakai
Noriko Senoo
Yasushi Senoo
Toshiro Ito
Hiroshi Saito
Hideyuki Nakazawa
Tomonobu Koizumi
Fumihiro Ishida
Publication date
01-06-2017
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 6/2017
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-016-2170-4

Other articles of this Issue 6/2017

International Journal of Hematology 6/2017 Go to the issue

Original Article

Transgenic expression of a canonical Wnt inhibitor, kallistatin, is associated with decreased circulating CD19+ B lymphocytes in the peripheral blood

Progress in Hematology

Somatic SETBP1 mutations in myeloid neoplasms

Progress in Hematology

Splicing factor mutations in MDS RARS and MDS/MPN-RS-T

Original Article

Over-expression of miR-196b-5p is significantly associated with the progression of myelodysplastic syndrome

Original Article

The first validated criteria for effective screening and a new simplified method for α-globin gene sequencing for diagnosis of uncommon α-globin mutations

Original Article

The fibrous form of intracellular inclusion bodies in recombinant variant fibrinogen-producing cells is specific to the hepatic fibrinogen storage disease-inducible variant fibrinogen
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits